BR112023018921A2 - Métodos para tratar câncer com anticorpos anti-ilt3 - Google Patents

Métodos para tratar câncer com anticorpos anti-ilt3

Info

Publication number
BR112023018921A2
BR112023018921A2 BR112023018921A BR112023018921A BR112023018921A2 BR 112023018921 A2 BR112023018921 A2 BR 112023018921A2 BR 112023018921 A BR112023018921 A BR 112023018921A BR 112023018921 A BR112023018921 A BR 112023018921A BR 112023018921 A2 BR112023018921 A2 BR 112023018921A2
Authority
BR
Brazil
Prior art keywords
antigen
methods
metastatic
ilt3
treating cancer
Prior art date
Application number
BR112023018921A
Other languages
English (en)
Inventor
Andrey Loboda
Cai Wu
Daping Zhang
Jie Zhang-Hoover
Mei Chen
Michael Nebozhyn
E Brandish Philip
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of BR112023018921A2 publication Critical patent/BR112023018921A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

métodos para tratar câncer com anticorpos anti-ilt3. esta revelação está relacionada a métodos para tratar tumores sólidos em um paciente identificado como tendo câncer de mama triplo negativo metastático, glioblastoma, adenocarcinoma ductal pancreático metastático, sarcoma metastático de tecidos moles ou carcinoma pulmonar metastático não escamoso de células não pequenas, compreendendo a administração de uma proteína de ligação ao antígeno anti-ilt3, ou fragmento de ligação ao antígeno, e uma proteína de ligação ao antígeno anti-pd1, ou fragmento de ligação ao antígeno, ao paciente a cada três semanas (q3w).
BR112023018921A 2021-03-19 2022-03-17 Métodos para tratar câncer com anticorpos anti-ilt3 BR112023018921A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163163779P 2021-03-19 2021-03-19
PCT/US2022/020714 WO2022197900A1 (en) 2021-03-19 2022-03-17 Methods for treating cancer with anti-ilt3 antibodies

Publications (1)

Publication Number Publication Date
BR112023018921A2 true BR112023018921A2 (pt) 2023-12-05

Family

ID=83320983

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023018921A BR112023018921A2 (pt) 2021-03-19 2022-03-17 Métodos para tratar câncer com anticorpos anti-ilt3

Country Status (8)

Country Link
EP (1) EP4308243A1 (pt)
JP (1) JP2024511977A (pt)
KR (1) KR20230158057A (pt)
CN (1) CN117412771A (pt)
AU (1) AU2022239502A1 (pt)
BR (1) BR112023018921A2 (pt)
CA (1) CA3212604A1 (pt)
WO (1) WO2022197900A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7194481B2 (ja) * 2017-11-17 2022-12-22 メルク・シャープ・アンド・ドーム・エルエルシー 免疫グロブリン様転写産物３（ｉｌｔ３）に特異的な抗体およびその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019008032A (es) * 2017-01-20 2019-12-16 Exelixis Inc Combinaciones de cabozantinib y atezolizumab para tratar cancer.
JP7194481B2 (ja) * 2017-11-17 2022-12-22 メルク・シャープ・アンド・ドーム・エルエルシー 免疫グロブリン様転写産物３（ｉｌｔ３）に特異的な抗体およびその使用
CN112469730A (zh) * 2018-05-10 2021-03-09 加利福尼亚大学董事会 用于治疗癌症的ccl21和检查点抑制剂

Also Published As

Publication number Publication date
CA3212604A1 (en) 2022-09-22
KR20230158057A (ko) 2023-11-17
AU2022239502A1 (en) 2023-10-05
JP2024511977A (ja) 2024-03-18
WO2022197900A1 (en) 2022-09-22
EP4308243A1 (en) 2024-01-24
CN117412771A (zh) 2024-01-16
AU2022239502A9 (en) 2024-02-22

Similar Documents

Publication Publication Date Title
BR112019010356A2 (pt) molécula de carboidrato, conjugado fármaco-anticorpo (adc), composição, método para preparar a composição, método para tratar câncer em um indivíduo, método para induzir ou melhorar a reação imune em um indivíduo necessitando do mesmo, composto conjugado de fármaco-anticorpo, uso de um composto conjungado anticorpo-fáramco, método para determinar a eficácia terapêutica de células de câncer ao adcc e método para fazer imagem de um indivíduo
TW201129380A (en) Methods of treating metastatic breast cancer with trastuzumab-MCC-DM1
MX344355B (es) Uso de inhibidores de erbb3 en el tratamiento de canceres de mama triple negativos y de tipo basal.
MX2021008605A (es) Arn terapéutico y anticuerpos anti-pd1 para canceres de tumor sólido en estadio avanzado.
MX2019006331A (es) Métodos para tratar el cáncer usando anticuerpos anti-pd-l1 y antiandrógenos.
MX340724B (es) Terapia anti-angiogenesis para el tratamiento del cancer de mama.
MX2020006171A (es) Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer.
CY1114552T1 (el) Αντινεοπλασματικοι συνδυασμοι που περιεχουν ηκι-272 και βινορελμπινη
BR112021008549A2 (pt) Método de tratamento de carcinoma pulmonar de células não pequenas com uma população de linfócitos infiltrantes de tumor
ZA201907225B (en) Treatment of her2 positive cancers
BR112015027607A8 (pt) métodos de tratamento de câncer de mama, de câncer da próstata, de câncer carcinoide, de câncer do ovário e de câncer do pulmão em pacientes.
CY1121667T1 (el) Παραγοντες για θεραπεια τριπλα αρνητικου καρκινου μαστου
BR112023018921A2 (pt) Métodos para tratar câncer com anticorpos anti-ilt3
BR112022026236A2 (pt) Terapia de combinação de imuno-oncologia com conjugados de il-2 e anticorpos anti-egfr
CL2020003204A1 (es) Tratamiento de nsclc en etapa iii y mitigación de condiciones patológicas asociadas al tratamiento
MX2021002241A (es) Uso de linfocitos infiltrantes de tumor para tratar pacientes con carcinoma de pulmón de células no pequeñas (nsclc) refractario al anticuerpo anti muerte programada 1 (pd-1).
MX2021003062A (es) Terapia combinada para tratar el cancer de sangre.
MX2021003214A (es) Metodos terapeuticos y de diagnostico para el cancer de vejiga.
CR20220127A (es) Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
Ji et al. Tumor‑penetrating peptide fused EGFR single‑domain antibody enhances radiation responses following EGFR inhibition in gastric cancer Corrigendum in/10.3892/or. 2020.7834
MX336476B (es) Terapia anti-angiogenesis para el tratamiento de cancer de mama previamente tratado.
MX2021002884A (es) Terapia de combinacion para el tratamiento de cancer de prostata.
MX2022016232A (es) Marcadores para uso en metodos para tratar canceres con conjugados de anticuerpo y farmaco (adc).
ATE499378T1 (de) Anthracyclinderivate
Rades et al. The effect of low hemoglobin levels on outcomes of radiotherapy following microscopically complete resection of locally advanced SCCHN: Implications for the future